$198 Million is the total value of Opaleye Management Inc.'s 36 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CMRX | Buy | CHIMERIX INC | $32,409,000 | -99.8% | 805,000 | +6.6% | 16.38% | +0.8% |
| AGIO | AGIOS PHARMACEUTICALS INC | $12,717,000 | -99.8% | 113,500 | 0.0% | 6.43% | +18.4% | |
| CEMP | CEMPRA INC | $11,868,000 | -99.8% | 504,800 | 0.0% | 6.00% | +39.1% | |
| RTRX | Sell | RETROPHIN INC | $11,261,000 | -99.9% | 920,000 | -8.0% | 5.69% | -19.1% |
| ARIA | Buy | ARIAD PHARMACEUTICALS INC | $10,477,000 | -99.9% | 1,525,000 | +1.7% | 5.29% | -16.2% |
| PCYC | PHARMACYCLICS INC | $10,392,000 | -99.9% | 85,000 | 0.0% | 5.25% | -32.5% | |
| CLVS | CLOVIS ONCOLOGY INC. | $7,840,000 | -99.9% | 140,000 | 0.0% | 3.96% | -18.2% | |
| TTPH | Buy | TETRAPHASE PHARMACEUTICALS INC | $7,533,000 | -99.8% | 189,700 | +11.8% | 3.81% | +44.3% |
| GERN | Buy | GERON CORP | $5,931,000 | -99.6% | 1,825,000 | +122.6% | 3.00% | +134.5% |
| VSAR | New | VERSARTIS INC | $5,276,000 | – | 235,000 | +100.0% | 2.67% | – |
| FGEN | New | FIBROGEN INC | $5,231,000 | – | 191,338 | +100.0% | 2.64% | – |
| INSYQ | INSYS THERAPEUTICS INC NEW | $5,165,000 | -99.9% | 122,500 | 0.0% | 2.61% | -29.5% | |
| RARE | Buy | ULTRAGENYX PHARMACEUTICALS INC | $4,660,000 | -99.9% | 106,200 | +24.9% | 2.36% | -37.2% |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $4,559,000 | -99.9% | 335,000 | -39.1% | 2.30% | -40.1% |
| OPHT | Buy | OPHTHOTECH CORP | $4,487,000 | -99.7% | 100,000 | +185.7% | 2.27% | +113.5% |
| KITE | New | KITE PHARMA INC | $4,383,000 | – | 76,000 | +100.0% | 2.22% | – |
| CDXS | Buy | CODEXIS INC | $4,344,000 | -99.9% | 1,724,000 | +2.0% | 2.20% | -28.5% |
| MDGN | New | MEDGENICS INC | $4,301,000 | – | 850,000 | +100.0% | 2.17% | – |
| IMMY | Buy | IMPRIMIS PHARMACEUTICALS INC | $4,200,000 | -99.9% | 560,000 | +11.4% | 2.12% | -27.0% |
| New | ONCOTHYREON INC | $3,800,000 | – | 2,000,000 | +100.0% | 1.92% | – | |
| CSII | CARDIOVASCULAR SYS INC DEL | $3,760,000 | -99.9% | 125,000 | 0.0% | 1.90% | -17.5% | |
| FLML | New | FLAMEL TECHNOLOGIES SA | $3,512,000 | – | 205,000 | +100.0% | 1.78% | – |
| FLDM | Buy | FLUIDIGM CORP DEL | $3,204,000 | -99.8% | 95,000 | +41.8% | 1.62% | +26.6% |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $3,084,000 | – | 80,000 | +100.0% | 1.56% | – |
| New | TRILLIUM THERAPEUTICS INC | $3,000,000 | – | 333,333 | +100.0% | 1.52% | – | |
| SUPN | New | SUPERNUS PHARMACEUTICALS INC | $2,905,000 | – | 350,000 | +100.0% | 1.47% | – |
| CPRX | CATALYST PHARM PARTNERS INC | $2,896,000 | -99.9% | 975,000 | 0.0% | 1.46% | -42.0% | |
| HZNP | New | HORIZON PHARMA PLC | $2,836,000 | – | 220,000 | +100.0% | 1.43% | – |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $2,823,000 | -99.9% | 29,100 | 0.0% | 1.43% | -19.5% | |
| AXDX | Buy | ACCELERATE DIAGNOSTICS | $1,919,000 | -99.9% | 100,000 | +12.1% | 0.97% | -35.0% |
| CELGZ | Sell | CELGENE CORPright 12/31/2030 | $1,811,000 | -99.9% | 575,000 | -12.9% | 0.92% | -47.5% |
| TENX | New | TENAX THERAPEUTICS INC | $1,690,000 | – | 440,000 | +100.0% | 0.85% | – |
| EVOK | Sell | EVOKE PHARMA INC | $1,416,000 | -99.9% | 240,000 | -10.1% | 0.72% | -37.5% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $1,005,000 | – | 45,000 | +100.0% | 0.51% | – |
| CARA | New | CARA THERAPEUTICS INC | $798,000 | – | 80,000 | +100.0% | 0.40% | – |
| BLRX | Sell | BIOLINERX LTD | $405,000 | -99.9% | 250,000 | -49.0% | 0.20% | -65.1% |
| KIPS | Exit | KIPS BAY MED INC | $0 | – | -50,000 | -100.0% | -0.01% | – |
| CPXX | Exit | CELATOR PHARMACEUTICALS INC | $0 | – | -405,000 | -100.0% | -0.80% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -134,500 | -100.0% | -1.34% | – |
| AEGR | Exit | AEGERION PHARMACEUTICALS INC | $0 | – | -57,500 | -100.0% | -1.50% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -157,000 | -100.0% | -2.71% | – |
| BINDQ | Exit | BIND THERAPEUTICS INC | $0 | – | -450,000 | -100.0% | -3.01% | – |
| NSPR | Exit | INSPIREMD INC | $0 | – | -2,088,500 | -100.0% | -3.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.